Uterine fibroids — why you should choose tailored therapies based on the joint decision of the physician and the patient
Uterine fibroids (UFs) are the most common benign tumors of the myometrium, affecting up to 70% women by age 50. Although many cases remain asymptomatic, symptomatic UFs can significantly reduce quality of life through excessive bleeding, anemia, pelvic pain, infertility, and obstetric complications...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Via Medica
2025-07-01
|
| Series: | Ginekologia Polska |
| Subjects: | |
| Online Access: | https://journals.viamedica.pl/ginekologia_polska/article/view/107627 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849230410652844032 |
|---|---|
| author | Michal Ciebiera Tomasz Lozinski Ayman Al-Hendy |
| author_facet | Michal Ciebiera Tomasz Lozinski Ayman Al-Hendy |
| author_sort | Michal Ciebiera |
| collection | DOAJ |
| description | Uterine fibroids (UFs) are the most common benign tumors of the myometrium, affecting up to 70% women by age 50. Although many cases remain asymptomatic, symptomatic UFs can significantly reduce quality of life through excessive bleeding, anemia, pelvic pain, infertility, and obstetric complications. Despite the availability of various conservative treatments — including pharmacotherapy, uterine artery embolization, and ultrasound thermoablation — surgical interventions, particularly hysterectomy, remain the dominant approach in many countries. This discrepancy between evidence-based recommendations and routine practice highlights the persistence of a paternalistic model of care, where patients are often excluded from treatment decisions and not informed about alternatives. Emerging concepts such as shared decision making (SDM) and personalized therapy emphasize the need to adapt treatment plans to each woman’s clinical profile, reproductive goals, and preferences. SDM fosters trust, better adherence to therapy, and improved acceptance of complications by actively involving patients in choosing their care. The development of modern pharmacological options, like GnRH analogs, further expands possibilities for effective, reversible, fertility-preserving treatments. A paradigm shift toward patient-centered, individualized management is essential to address ethical challenges, reduce unnecessary hysterectomies, and improve outcomes. Implementing SDM and expanding access to conservative therapies require systemic changes in reimbursement, training, and patient education to ensure that care focuses not only on the disease but on the woman as a whole. |
| format | Article |
| id | doaj-art-fbb56e82acce47dcb739c8874cdc6739 |
| institution | Kabale University |
| issn | 0017-0011 2543-6767 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Via Medica |
| record_format | Article |
| series | Ginekologia Polska |
| spelling | doaj-art-fbb56e82acce47dcb739c8874cdc67392025-08-21T06:11:43ZengVia MedicaGinekologia Polska0017-00112543-67672025-07-0196710.5603/gpl.107627Uterine fibroids — why you should choose tailored therapies based on the joint decision of the physician and the patientMichal Ciebiera0https://orcid.org/0000-0001-5780-5983Tomasz Lozinski1https://orcid.org/0000-0002-5129-5262Ayman Al-Hendy2https://orcid.org/0000-0002-8778-4447Second Department of Obstetrics and Gynecology, Center of Postgraduate Medical Education, Warsaw, PolandDevelopment and Research Center of Non-Invasive Therapies, Pro-Familia Hospital, Rzeszow, PolandDepartment of Medical Sciences, Khalifa University, Abu Dhabi, United Arab EmiratesUterine fibroids (UFs) are the most common benign tumors of the myometrium, affecting up to 70% women by age 50. Although many cases remain asymptomatic, symptomatic UFs can significantly reduce quality of life through excessive bleeding, anemia, pelvic pain, infertility, and obstetric complications. Despite the availability of various conservative treatments — including pharmacotherapy, uterine artery embolization, and ultrasound thermoablation — surgical interventions, particularly hysterectomy, remain the dominant approach in many countries. This discrepancy between evidence-based recommendations and routine practice highlights the persistence of a paternalistic model of care, where patients are often excluded from treatment decisions and not informed about alternatives. Emerging concepts such as shared decision making (SDM) and personalized therapy emphasize the need to adapt treatment plans to each woman’s clinical profile, reproductive goals, and preferences. SDM fosters trust, better adherence to therapy, and improved acceptance of complications by actively involving patients in choosing their care. The development of modern pharmacological options, like GnRH analogs, further expands possibilities for effective, reversible, fertility-preserving treatments. A paradigm shift toward patient-centered, individualized management is essential to address ethical challenges, reduce unnecessary hysterectomies, and improve outcomes. Implementing SDM and expanding access to conservative therapies require systemic changes in reimbursement, training, and patient education to ensure that care focuses not only on the disease but on the woman as a whole.https://journals.viamedica.pl/ginekologia_polska/article/view/107627uterine fibroidleiomyomapatient-tailored therapyshared decision makingtherapy |
| spellingShingle | Michal Ciebiera Tomasz Lozinski Ayman Al-Hendy Uterine fibroids — why you should choose tailored therapies based on the joint decision of the physician and the patient Ginekologia Polska uterine fibroid leiomyoma patient-tailored therapy shared decision making therapy |
| title | Uterine fibroids — why you should choose tailored therapies based on the joint decision of the physician and the patient |
| title_full | Uterine fibroids — why you should choose tailored therapies based on the joint decision of the physician and the patient |
| title_fullStr | Uterine fibroids — why you should choose tailored therapies based on the joint decision of the physician and the patient |
| title_full_unstemmed | Uterine fibroids — why you should choose tailored therapies based on the joint decision of the physician and the patient |
| title_short | Uterine fibroids — why you should choose tailored therapies based on the joint decision of the physician and the patient |
| title_sort | uterine fibroids why you should choose tailored therapies based on the joint decision of the physician and the patient |
| topic | uterine fibroid leiomyoma patient-tailored therapy shared decision making therapy |
| url | https://journals.viamedica.pl/ginekologia_polska/article/view/107627 |
| work_keys_str_mv | AT michalciebiera uterinefibroidswhyyoushouldchoosetailoredtherapiesbasedonthejointdecisionofthephysicianandthepatient AT tomaszlozinski uterinefibroidswhyyoushouldchoosetailoredtherapiesbasedonthejointdecisionofthephysicianandthepatient AT aymanalhendy uterinefibroidswhyyoushouldchoosetailoredtherapiesbasedonthejointdecisionofthephysicianandthepatient |